Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 11, 2010, Pages 2877-2887

  Gu, Fangyi ^a   Schumacher, Fredrick R ^b   Canzian, Federico ^c   Allen, Naomi E ^d   Albanes, Demetrius ^e   Berg, Christine D ^e   Berndt, Sonja I ^e   Boeing, Heiner ^f   Bueno de Mesquita, H Bas ^g   Buring, Julie E ^a,h,i   Chabbert Buffet, Nathalie ^j   Chanock, Stephen J ^e   Clavel Chapelon, Françoise ^k,l   Dumeaux, Vanessa ^m   Gaziano, J Michael ^h,i,n   Giovannucci, Edward L ^a   Haiman, Christopher A ^b   Hankinson, Susan E ^a,h,i   Hayes, Richard B ^e,o   Henderson, Brian E ^b   Hunter, David J ^a   Hoover, Robert N ^e   Johansson, Mattias ^p,q   Key, Timothy J ^d   Khaw, Kay Tee ^r   Kolonel, Laurence N ^s,t   Lagiou, Pagona ^u   Lee, I Min ^a,h,i   LeMarchand, Loic ^t   Lund, Eiliv ^m   Ma, Jing ^h,i   Onland Moret, N Charlotte ^v   Overvad, Kim ^w   Rodriguez, Laudina ^x   Sacerdote, Carlotta ^y   Sánchez, Maria José ^z,aa   Stampfer, Meir J ^a,h,i   Stattin, Pär ^q   Stram, Daniel O ^b   Thomas, Gilles ^e   Thun, Michael J ^ab   Tjønneland, Anne ^ac   Trichopoulos, Dimitrios ^a,ad   Tumino, Rosario ^ae   Virtamo, Jarmo ^af   Weinstein, Stephanie J ^e   Willett, Walter C ^a   Yeager, Meredith ^e   Zhang, Shumin M ^h,i   Kaaks, Rudolf ^c   Riboli, Elio ^ag   Ziegler, Regina G ^e   Kraft, Peter ^a   more..

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e NATIONAL CANCER INSTITUTE   (United States)

^f GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^g NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j HÔPITAL TENON   (France)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l UNIVERSITÉ PARIS SACLAY   (France)

^m UNIVERSITY OF TROMSØ   (Norway)

ⁿ VA BOSTON HEALTHCARE SYSTEM   (United States)

^o NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^p INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^q UMEÅ UNIVERSITY   (Sweden)

^r UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^s UNIVERSITY OF HAWAII   (United States)

^t UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^u UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^v UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^w AARHUS UNIVERSITY   (Denmark)

^x Health and Health Care Services Council   (Spain)

^y Human Genetics Foundation   (Italy)

^z ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^aa CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^ab AMERICAN CANCER SOCIETY   (United States)

^ac INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^ad BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^ae CIVILE M P AREZZO HOSPITAL   (Italy)

^af NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^ag IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR 5;

ARTICLE; BREAST CANCER; CANCER RISK; CAUCASIAN; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; IGFALS GENE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BREAST NEOPLASMS; CARRIER PROTEINS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCOPROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 78549247522     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0507     Document Type: Article

References (59)

1. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
2. Group EHaBCC. Insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), and breast cancer risk: reanalysis of seventeen prospective studies. Lancet Oncol 2010.
3. Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008;149:461-71, W83-8.
4. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 2009;124:2416-29.
5. Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 2006;13:273-8.
6. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994;15:80-101.
7. Hall K, Hilding A, Thoren M. Determinants of circulating insulin-like growth factor-I. J Endocrinol Invest 1999;22:48-57.
8. Harrela M, Koistinen H, Kaprio J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996;98:2612-5.
9. Al-Zahrani A, Sandhu MS, Luben RN, et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 2006;15:1-10.
10. Canzian F, McKay JD, Cleveland RJ, et al. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 2006;94:299-307.
11. Fletcher O, Gibson L, Johnson N, et al. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:2-19.
12. Johansson M, McKay JD, Wiklund F, et al. Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels. J Clin Endocrinol Metab 2007;92:4820-6.
13. Johansson M, McKay JD, Wiklund F, et al. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18:1644-50.
14. Filopanti M, Ronchi C, Ballare E, et al. Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. J Clin Endocrinol Metab 2005;90:4824-8.
15. Canzian F, McKay JD, Cleveland RJ, et al. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study. Cancer Epidemiol Biomarkers Prev 2005;14:2316-25.
16. Schumacher FR, Cheng I, Freedman ML, et al. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-1 and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet 2010;19:3089-101.
17. Patel AV, Cheng I, Canzian F, et al. IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One 2008;3:e2578.
18. Canzian F, Cox DG, Setiawan W, et al. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI Breast and Prostate Cancer Cohort Consortium. Hum Mol Genet 2010;19:3873-84.
19. Hunter DJ, Riboli E, Haiman CA, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005;5:977-85.
20. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000;151:346-57.
21. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-106.
22. Giovannucci E, Pollak M, Liu Y, et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 2003;12:84-9.
23. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
24. Hayes RB, Reding D, Kopp W, et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21:349-55S.
25. The ATBC Cancer Prevention Study Group. The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study: design, methods, participant characteristics, and compliance. Ann Epidemiol 1994;4:1-10.
26. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 2005;5:388-96.
27. Cheng I, DeLellis Henderson K, Haiman CA, et al. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab 2007;92:3660-6.
28. DeLellis K, Ingles S, Kolonel L, et al. IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort. Br J Cancer 2003;88:277-82.
29. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005;16:255-62.
30. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:699-704.
31. Weiss JM, Huang WY, Rinaldi S, et al. IGF-1 and IGFBP-3: risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer 2007;121:2267-73.
32. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res 2003;63:3991-4.
33. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9.
34. Available from: http://cebp.aacrjournals.org/site/misc/ifora.xhtml.
35. Stram DO, Haiman CA, Hirschhorn JN, et al. Choosing haplotype-tagging SNPs based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36.
36. Available from: http://www.broad.mit.edu/mpg/tagger/.
37. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217-23.
38. Packer BR, Yeager M, Staats B, et al. SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 2004;32:D528-32.
39. Available from: http://cgf1.nci.nih.gov/cohort.cfm.
40. Available from: http://www.sph.umich.edu/csg/abecasis/MaCH/index.html.
41. Marchini J, Howie B. Comparing algorithms for genotype imputation. Am J Hum Genet 2008;83:535-9, author reply 9-40.
42. Rosner B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 1983:165-72.
43. Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med 2008;27:625-50.
44. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
45. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol 2008;32:361-9.
46. Baxter RC, Martin JL, Beniac VA. High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum. J Biol Chem 1989;264:11843-8.
47. Baxter RC. Circulating levels and molecular distribution of the acid-labile (α) subunit of the high molecular weight insulin-like growth factor-binding protein complex. J Clin Endocrinol Metab 1990;70:1347-53.
48. Twigg SM, Baxter RC. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. J Biol Chem 1998;273:6074-9.
49. Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 1989;121:753-8.
50. Bertherat J, Tenenbaum F, Perlemoine K, et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab 2003;88:5353-60.
51. Tamimi RM, Cox DG, Kraft P, et al. Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res 2007;9:R18.
52. Chen C, Freeman R, Voigt LF, Fitzpatrick A, Plymate SR, Weiss NS. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor. Cancer Epidemiol Biomarkers Prev 2006;15:2461-6.
53. Deal C, Ma J, Wilkin F, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001;86:1274-80.
54. Jernstrom H, Deal C, Wilkin F, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:377-84.
55. Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA. A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiol Biomarkers Prev 2004;13:573-82.
56. Ren Z, Cai Q, Shu XO, et al. Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 2004;13:1290-5.
57. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 2003;107:60-4.
58. Le Marchand L, Kolonel LN, Henderson BE, Wilkens LR. Association of an exon 1 polymorphism in the IGFBP3 gene with circulating IGFBP-3 levels and colorectal cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 2005;14:1319-21.
59. Kao PC, Matheny AP, Jr., Lang CA. Insulin-like growth factor-I comparisons in healthy twin children. J Clin Endocrinol Metab 1994;78:310-2.